Half-time at PneumoNP
EU project successfully holds 4th Progress Meeting in Hannover
With the start of the new year, PneumoNP has entered its second project half and held its 4th Progress Meeting in Hannover, Germany on January 26-27, 2016 hosted by PneumoNP partner Fraunhofer Institute for Toxicology and Experimental Medicine (Fraunhofer ITEM).
The meeting started off with a keynote speech of Wolfgang Koch (Fraunhofer ITEM) on the generation of aerosols for inhalation which was followed by a talk of PneumoNP’s External Advisory Board member Iseult Lynch of the University of Birmingham on the subject of NP interactions at the air-lung interface. Both speeches fitted well into the subject and triggered lively discussions among the consortium. After a session on the progress the project has made in the past six months, the first day was rounded up with a keynote talk of José Bengoechea of Queen’s University Belfast, another External Advisory Board member, on Klebsiella pneumoniae and a visit to ITEM’s in vitro and mechanistic toxicology facilities as well as in vivo inhalation animal facilities.
The second day was entirely dedicated to discussions on the way forward. The selection of the best nanosystems for further experiments is of utmost importance at this stage for a successful outcome of the project. While some decisions had been made already within the scope of the last meeting six months earlier, the discussions this time followed up on this and final decisions were made. The consortium will continue to work closely together on the goal to find alternatives to standard treatment with antibiotics.
The next meeting will take place in Bremen in July 2016 and it will be connected to PneumoNP’s 1st workshop. The workshop will be jointly organized by PneumoNP with its cluster projects NAREB and FORMAMP and jointly hosted with the IMI Initiative TRANSLOCATION.
PneumoNP is a 4-year collaborative project funded by the European Commission under the 7th Framework Programme. It aims to develop a theragnostic system for the treatment of Gram-negative bacterial infections in lungs.
European Research and Project Office GmbH
Tel.:+49 681 9592 3357
Tags: Horizon 2020